Hepion Pharmaceuticals Gestione
Gestione criteri di controllo 2/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
John Brancaccio
Amministratore delegato
US$81.0k
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | less than a year |
| Proprietà del CEO | 0.006% |
| Durata media del management | Nessun dato |
| Durata media del Consiglio di amministrazione | 2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Hepion Pharmaceuticals (NASDAQ:HEPA) Will Have To Spend Its Cash Wisely
Aug 10
We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Apr 25We're Keeping An Eye On Hepion Pharmaceuticals' (NASDAQ:HEPA) Cash Burn Rate
Oct 27Hepion Pharma rises as company begins NASH treatment trial
Aug 31Will Hepion Pharmaceuticals (NASDAQ:HEPA) Spend Its Cash Wisely?
Jul 04Hepion Pharmaceuticals CEO Robert Foster - Dash To Beat NASH
Feb 17Hepion Pharmaceuticals: Facing The Momentous Year 2022
Jan 21Additional Phase IIa Data Confirms Hepion's CRV431 As A Very Promising NASH Candidate Drug
Sep 21Companies Like Hepion Pharmaceuticals (NASDAQ:HEPA) Are In A Position To Invest In Growth
Sep 14Hepion Pharmaceuticals: A Promising Early-Stage Biopharma In The NASH Race
Sep 08Treating Chronic Liver Disease - Interview With Hepion Pharmaceuticals CEO Dr. Robert Foster (Video)
May 26What Type Of Shareholders Make Up Hepion Pharmaceuticals, Inc.'s (NASDAQ:HEPA) Share Registry?
Feb 18Hepion Pharma cleared to advance final dosing cohort in NASH trial
Dec 29Hepion Pharma to begin CRV431 testing in COVID-19 patients
Dec 22Dosing underway in higher dose cohort with Hepion's CRV431 in NASH study
Dec 10Hepion Pharma prices equity offering at $1.50
Nov 25Hepion Pharmaceuticals (HEPA) Investor Presentation - Slideshow
Oct 31AMMINISTRATORE DELEGATO
John Brancaccio (76 yo)
less than a year
Mandato
US$81,000
Compensazione
Mr. John Patrick Brancaccio, C.P.A, serves as Independent Non-Executive Director at Tiziana Life Sciences plc since July 2020. He is an Independent Non-Executive Director at OKYO Pharma Limited since June...
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Interim CEO | 11.5yrs | US$81.00k | 0.0060% $ 242.1 | |
| Independent Director | 11yrs | US$72.90k | 0.0060% $ 242.1 | |
| Member of Scientific Advisory Board | 1.7yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 1.7yrs | Nessun dato | Nessun dato | |
| Scientific Advisory Board Chair | 5.3yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 1.7yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 8.3yrs | Nessun dato | Nessun dato | |
| Independent Director | less than a year | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 1.7yrs | Nessun dato | Nessun dato | |
| Independent Director | 2.4yrs | US$80.50k | Nessun dato |
2.0yrs
Durata media
68yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di HEPA non è considerato esperto (durata media del mandato 2 anni), il che suggerisce un nuovo consiglio.